CNSP · CNS Pharmaceuticals, Inc. · Documents
Market Cap
$8.68M
Shares
1.46M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| DEF 14A | 2026-08-21 | 2026-09-30 | |
| 10-Q | 2026-08-12 | 2026-06-30 | |
| 8-K | 2026-07-02 | — | |
| 10-Q | 2026-05-14 | 2026-03-31 | |
| 8-K | 2026-05-04 | — | |
| 10-K/A | 2026-04-30 | 2025-12-31 | |
| 10-K | 2026-03-31 | 2025-12-31 | |
| 8-K | 2026-03-11 | — | |
| 8-K | 2026-03-02 | 2026-02-26 | |
| 8-K | 2026-02-17 | 2026-02-10 | |
| 8-K | 2025-12-17 | 2025-12-16 | |
| 8-K | 2025-11-21 | 2025-11-17 | |
| 10-Q | 2025-11-14 | 2025-09-30 | |
| DEF 14A | 2025-10-24 | 2025-11-17 | |
| 10-Q | 2025-08-14 | 2025-06-30 | |
| 8-K | 2025-07-22 | 2025-07-17 | |
| 8-K | 2025-07-15 | — | |
| 10-Q | 2025-05-15 | 2025-03-31 | |
| 8-K | 2025-05-15 | 2025-05-13 | |
| 10-K/A | 2025-04-30 | 2024-12-31 | |
| 8-K | 2025-04-09 | — | |
| 10-K | 2025-03-31 | 2024-12-31 | |
| 8-K | 2025-03-31 | — | |
| 8-K | 2025-03-20 | — | |
| 8-K | 2025-02-21 | 2025-02-19 | |
| 8-K | 2025-01-03 | — | |
| 8-K | 2024-12-11 | — | |
| 8-K | 2024-12-03 | 2024-11-26 | |
| 10-Q | 2024-11-14 | 2024-09-30 | |
| 8-K | 2024-11-01 | 2024-10-30 | |
| DEF 14A | 2024-10-28 | 2024-11-26 | |
| 8-K | 2024-10-24 | 2024-10-23 | |
| 8-K | 2024-10-23 | — | |
| 8-K | 2024-09-18 | 2024-09-12 | |
| 8-K | 2024-09-12 | 2024-09-10 | |
| 10-Q | 2024-08-14 | 2024-06-30 | |
| 8-K | 2024-08-07 | 2024-08-06 | |
| 8-K | 2024-07-30 | 2024-07-29 | |
| 8-K | 2024-07-30 | — | |
| 8-K | 2024-07-26 | — | |
| 8-K | 2024-07-24 | 2024-07-19 | |
| 8-K/A | 2024-07-12 | 2024-07-05 | |
| 8-K | 2024-07-09 | 2024-07-05 | |
| 8-K | 2024-07-03 | — | |
| 8-K | 2024-06-26 | — | |
| 8-K/A | 2024-06-20 | 2024-06-14 | |
| 8-K | 2024-06-14 | — | |
| 8-K | 2024-06-05 | 2024-06-03 | |
| 8-K | 2024-05-16 | — | |
| 10-Q | 2024-05-15 | 2024-03-31 |
Showing 1–50 of 141 filings
Key facts
CIK
1729427
CUSIP
18978H508
13F (30d)
10 filings
10 filers
Visit website
Investor relations